The Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) is designed to reduce chronic adverse cardiovascular events that may occur from the permanent presence of a metallic stent and/or durable polymer. The systemic pharmacokinetic (PK) profile of BVS has not been described.
Although short-lived, individual C max values (1.085 to 4.460 ng/ml) were slightly higher than the minimum systemic, chronically maintained therapeutic level of $3.0 ng/ml required for effective prevention of organ rejection (4). However, everolimus blood concentrations declined rapidly after reaching C max and were <3.0 ng/ml in all subjects by 4 h after the last scaffold deployment. In addition, C max levels obtained after Absorb BVS were well below mean steady-state C max (61 ng/ml) observed in In conclusion, the systemic PK characteristics of Letters D E C E M B E R 1 , 2 0 1 5 : 2 4 6 7 -7 3
